- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03896503
Ensayo aleatorizado de topotecán con M6620, un inhibidor de la quinasa ATR, en cánceres de pulmón de células pequeñas y cánceres de células pequeñas fuera de los pulmones
Ensayo aleatorizado de fase II de topotecán más M6620 (VX-970, berzosertib) frente a topotecán solo en pacientes con cáncer de pulmón microcítico recidivante
This phase II trial studies how well berzosertib (M6620) works when given in combination with topotecan hydrochloride (topotecan) compared with topotecan alone in treating patients with small cell lung cancer that has come back (relapsed), or small cell cancer that arises from a site other than the lung (extrapulmonary). Drugs used in chemotherapy, such as topotecan hydrochloride, work by damaging the DNA (deoxyribonucleic acid) in tumor cells, causing those cells to die and the tumor to shrink. However, some tumor cells can become less affected by chemotherapy because they have ways to repair the damaged DNA. The addition of M6620 could help topotecan hydrochloride shrink the cancer and prevent it from returning by blocking enzymes needed for DNA repair.
Descripción general del estudio
Estado
Condiciones
- Carcinoma de células pequeñas de pulmón en estadio extenso
- Carcinoma de células pequeñas de pulmón en etapa limitada
- Carcinoma de células pequeñas de pulmón resistente al platino
- Carcinoma de células pequeñas de pulmón sensible al platino
- Carcinoma neuroendocrino extrapulmonar de células pequeñas
- Carcinoma de células pequeñas de pulmón recidivante
Descripción detallada
PRIMARY OBJECTIVE:
I. To determine if the combination of berzosertib (M6620) with topotecan hydrochloride (topotecan) will result in an improvement in progression-free survival (PFS) compared to topotecan alone in patients with relapsed small cell lung cancer (SCLC).
SECONDARY OBJECTIVE:
I. To determine the objective response rate (ORR) and overall survival (OS) with the combination of M6220 and topotecan in patients with relapsed SCLC and extrapulmonary small cell cancers.
EXPLORATORY OBJECTIVES:
I. To perform molecular profiling assays on malignant and normal tissues, including, but not limited to ribonucleic acid (RNA) sequencing (RNA-Seq):
Ia. To assess expression of genes Schlafen family member 11 (SLFN11), MYC, and ataxia-telangiectasia mutated (ATM) among others.
Ib. To identify potential predictive biomarkers of response to a combination of M6620 with topotecan.
Ic. Identify mechanisms of drug sensitivity and resistance using deoxyribonucleic acid (DNA)- and RNA-based assessment platforms.
II. To contribute genetic analysis data from de-identified biospecimens to Genomic Data Commons (GDC), a well annotated cancer molecular and clinical data repository, for current and future research; specimens will be annotated with key clinical data, including presentation, diagnosis, staging, summary treatment, and if possible, outcome.
III. To bank formalin-fixed, paraffin-embedded (FFPE) tissue, blood (for cell-free DNA analysis), and nucleic acids obtained from patients at the Early-Phase and Experimental Clinical Trials (EET) Biobank at Nationwide Children's Hospital.
IV. To characterize circulating cell-free DNA (cfDNA) and circulating tumor cells in patients with relapsed SCLC and extrapulmonary small cell cancers.
V. To identify potential predictive biomarkers of response to a combination of M6620 with topotecan in patients with extrapulmonary small cell cancers.
OUTLINE: Patients are assigned to 1 of 2 cohorts.
COHORT I: Patients with SCLC are randomized to 1 of 2 arms.
ARM I: Participants receive topotecan hydrochloride intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a computed tomography (CT) scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
ARM II: Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
COHORT II (Patients with extrapulmonary small cell cancer): Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study.
After completion of study treatment, patients are followed up at 4 weeks and then every 12 weeks thereafter.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
California
-
Los Angeles, California, Estados Unidos, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Estados Unidos, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Estados Unidos, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
Sacramento, California, Estados Unidos, 95817
- University of California Davis Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- UCHealth University of Colorado Hospital
-
-
Kansas
-
Fairway, Kansas, Estados Unidos, 66205
- University of Kansas Clinical Research Center
-
Hays, Kansas, Estados Unidos, 67601
- HaysMed
-
Kansas City, Kansas, Estados Unidos, 66160
- University of Kansas Cancer Center
-
Lawrence, Kansas, Estados Unidos, 66044
- Lawrence Memorial Hospital
-
Olathe, Kansas, Estados Unidos, 66061
- The University of Kansas Cancer Center - Olathe
-
Overland Park, Kansas, Estados Unidos, 66210
- University of Kansas Cancer Center-Overland Park
-
Overland Park, Kansas, Estados Unidos, 66211
- University of Kansas Hospital-Indian Creek Campus
-
Pittsburg, Kansas, Estados Unidos, 66762
- Mercy Hospital Pittsburg
-
Salina, Kansas, Estados Unidos, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Estados Unidos, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40536
- University of Kentucky/Markey Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Estados Unidos, 20892
- NCI - Center for Cancer Research
-
-
Michigan
-
Detroit, Michigan, Estados Unidos, 48201
- Wayne State University/Karmanos Cancer Institute
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Weisberg Cancer Treatment Center
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, Estados Unidos, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Estados Unidos, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Estados Unidos, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
-
New York
-
New York, New York, Estados Unidos, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
-
North Carolina
-
Clemmons, North Carolina, Estados Unidos, 27012
- Wake Forest University at Clemmons
-
Statesville, North Carolina, Estados Unidos, 28677
- Wake Forest Baptist Health - Hematology Oncology - Statesville
-
Wilkesboro, North Carolina, Estados Unidos, 28659
- Wake Forest Baptist Health - Wilkes Medical Center
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Wake Forest University Health Sciences
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patients enrolled to the primary cohort must have limited- or extensive-disease SCLC at diagnosis, with relapse at study entry with measurable disease at random assignment per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Both platinum-sensitive and platinum-resistant patients will be included
- Patients with extrapulmonary small cell cancers (cancers with small cell morphology and arising outside the lung, such as small cell prostate, bladder, etc.) will be eligible for the exploratory cohort
- Patients must be >= 18 years of age because no dosing or adverse event data are currently available on the use of M6620 in combination with topotecan in patients <18 years of age
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Hemoglobin >= 9.0 g/dL - patients may receive transfusion to meet the hemoglobin (Hb) eligibility
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin =< 2 mg/dL
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3.0 x institutional upper limit of normal (ULN)
- Creatinine =< institutional ULN OR
- Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m^2
- Human immunodeficiency virus (HIV)-positive subjects on combination antiretroviral therapy are eligible as long as they are on effective anti-retroviral therapy with undetectable viral load within 6 months and there is no drug-drug interaction with M6220
- For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
- Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
- The effects of M6620 on the developing human fetus are unknown. For this reason and because DNA-damage response (DDR) inhibitors as well as other therapeutic agents used in this trial are known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 6 months after completion of M6620 administration. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 6 months after completion of M6620 administration
- Patients with treated brain metastases are eligible if they are symptomatically stable while off steroid therapy for a minimum of 21 days
- Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
- Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
- Ability to understand and the willingness to sign a written informed consent document
Exclusion Criteria:
-
Patients with symptomatic brain metastasis are not eligible due to their extremely poor prognosis and since it is unclear whether the investigational agent penetrates the blood-brain barrier. However, subjects who have had treatment for their brain metastasis and are symptomatically stable while off steroid therapy for a minimum of 21 days may be enrolled
-
Patients who have received prior topotecan therapy
-
Patients who have had chemotherapy or radiotherapy within 3 weeks prior to enrollment.
- Note: Patients who have had palliative radiotherapy may be included as long as they have recovered from any radiotherapy related adverse events (allow at least a week between radiotherapy completion and study treatment)
-
Patients who have not recovered from adverse events due to prior anti-cancer therapy except hair loss and peripheral neuropathy (i.e., have residual toxicities > grade 1)
-
Patients who are receiving any other investigational agents
-
History of allergic reactions attributed to compounds of similar chemical or biologic composition to M6620 or topotecan used in study
-
M6620 is primarily metabolized by cytochrome P450 3A4 (CYP3A4); therefore, concomitant administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, indinavir, nelfinavir and saquinavir) or inducers of CYP3A4 (e.g., rifampin, phenytoin, carbamazepine, phenobarbital, St. John's wort) should be avoided. Patients requiring any medications or substances that are strong inhibitors or inducers of CYP3A during the course of the study are ineligible. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference for a list of drugs to avoid or of which to minimize use. The Patient Drug Interactions Handout and Wallet Card should be provided to patients. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
-
Patients with uncontrolled intercurrent illness
-
Pregnant women are excluded from this study because M6620 as a DDR inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with M6620, breastfeeding should be discontinued if the mother is treated with M6620. These potential risks may also apply to topotecan used in this study
-
Patients with high grade neuroendocrine cancers, but with no small cell morphology will not be eligible
-
Patients with psychiatric illness/social situations that would limit compliance with study requirements
-
Patients with Li-Fraumeni syndrome will not be eligible
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: Cohort I Arm I (topotecan hydrochloride)
Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants may crossover to Arm II at disease progression. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. |
Undergo blood sample collection
Otros nombres:
Given IV
Otros nombres:
Undergo a CT scan
Otros nombres:
Undergo a tumor biopsy
Otros nombres:
|
|
Experimental: Cohort I Arm II (topotecan hydrochloride, berzosertib (M6620))
Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. |
Undergo blood sample collection
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo a CT scan
Otros nombres:
Undergo a tumor biopsy
Otros nombres:
|
|
Experimental: Cohort II (exploratory cohort: topotecan, berzosertib (M6620))
Cohort II: Participants receive topotecan hydrochloride IV over 30 minutes on days 1-5 and berzosertib (M6620) IV over 60 minutes on days 2 and 5. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Participants undergo a CT scan during screening and on study as well as a tumor biopsy during screening. Participants may also undergo blood sample collection during screening and on study. |
Undergo blood sample collection
Otros nombres:
Given IV
Otros nombres:
Given IV
Otros nombres:
Undergo a CT scan
Otros nombres:
Undergo a tumor biopsy
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-free Survival (PFS) Reported With 80% Confidence Interval
Periodo de tiempo: From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
|
The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions. |
From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
|
|
Progression-free Survival (PFS) Reported With 95% Confidence Interval
Periodo de tiempo: From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
|
The combination of M6620 with topotecan will be compared to topotecan alone in participants with relapsed small cell lung cancer (SCLC). Kaplan-Meier curves and a one-tailed log-rank test will be the primary analysis methods. PFS is defined as the duration of time from start of treatment to time of progression or death. whichever occurs first. Progression was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1) and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study, and/or the appearance of one or more new lesions. |
From start of treatment to time of progression or death, whichever occurs first, assessed at 6 months after last participant has enrolled; up to 2 years for pulmonary cohort and up 31.5 months for Exploratory Cohort.
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response Rate (ORR)
Periodo de tiempo: Up to 2 years
|
ORR is defined as percentage of participants who achieved either complete response (CR) or partial response (PR) as best response assessed using the revised Response Evaluation Criteria in Solid Tumors guideline (v 1.1). ORR percentage is calculated as the sum of the PR and CR rates, divided by the total number of participants who are evaluable for a response, multiplied by 100%. All participants included in the study must be assessed for response to treatment, even if there are major protocol treatment deviations or if they are ineligible. Complete response is disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the diameters of target lesions. Stable disease is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease is at least a 20% increase in the sum of the diameters of target lesions. |
Up to 2 years
|
|
Overall Survival (OS) Reported With 80% Confidence Interval
Periodo de tiempo: Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort.
|
OS is defined as time from randomization to death, regardless of cause. |
Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort.
|
|
Overall Survival (OS) Reported With 95% Confidence Interval
Periodo de tiempo: Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort
|
OS is defined as time from randomization to death, regardless of cause. |
Up to 2 years for pulmonary cohort and up 31.5 for Exploratory Cohort
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0).
Periodo de tiempo: Date treatment consent signed to date off study, an average of 801.3 days.
|
Here is the number of participants with serious and/or non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. |
Date treatment consent signed to date off study, an average of 801.3 days.
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Arun Rajan, National Cancer Institute LAO
Publicaciones y enlaces útiles
Publicaciones Generales
- Takahashi N, Hao Z, Villaruz LC, Zhang J, Ruiz J, Petty WJ, Mamdani H, Riess JW, Nieva J, Pachecho JM, Fuld AD, Shum E, Chauhan A, Nichols S, Shimellis H, McGlone J, Sciuto L, Pinkiert D, Graham C, Shelat M, Kattappuram R, Abel M, Schroeder B, Upadhyay D, Krishnamurthy M, Sharma AK, Kumar R, Malin J, Schultz CW, Goyal S, Redon CE, Pommier Y, Aladjem MI, Gore SD, Steinberg SM, Vilimas R, Desai P, Thomas A. Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial. JAMA Oncol. 2023 Dec 1;9(12):1669-1677. doi: 10.1001/jamaoncol.2023.4025.
- Fialkoff G, Takahashi N, Sharkia I, Gutin J, Hermoni N, Nirula M, Kumar R, Pongor L, Nichols S, Sciuto L, Parmar K, Desai P, Suresh P, Abel M, El Meskini R, Maoz M, Rottenberg Y, Nevo S, Nechushtan H, Peretz T, Roame D, Hubert A, Cohen JE, Salah A, Temper M, Grinshpun A, Weaver-Ohler Z, Rajan A, Figg WD Sr, Zick A, Sadeh R, Friedman N, Thomas A. Plasma nucleosome profiling reports on tumor burden and molecular subtypes in small cell lung cancer. J Clin Invest. 2026 Oct 1;136(19):e202151. doi: 10.1172/JCI202151. eCollection 2026 Oct 1.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades de las vías respiratorias
- Enfermedades pulmonares
- Neoplasias de las vías respiratorias
- Neoplasias torácicas
- Neoplasias Pulmonares
- Carcinoma Broncogénico
- Neoplasias Bronquiales
- Carcinoma de pulmón de células pequeñas
- Compuestos heterocíclicos
- Técnicas de investigación
- Técnicas de laboratorio clínico
- Técnicas y procedimientos de diagnóstico
- Diagnóstico
- Procedimientos quirúrgicos, operativo
- Técnicas citológicas
- Citodiagnóstico
- Campeptecina
- Alcaloides
- Técnicas de diagnóstico, quirúrgico
- Topotecán
- Biopsia
- Manejo de muestras
- berzosertib
Otros números de identificación del estudio
- NCI-2019-01769
- ZIABC011078 (Subvención/contrato del NIH de EE. UU.)
- NCI-2019-01769 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- 20-C-0009
- 10268 (Otro identificador: CTEP)
- 10268 (Otro identificador: National Cancer Institute LAO)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .